AU2009246009A1 - Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy - Google Patents

Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy Download PDF

Info

Publication number
AU2009246009A1
AU2009246009A1 AU2009246009A AU2009246009A AU2009246009A1 AU 2009246009 A1 AU2009246009 A1 AU 2009246009A1 AU 2009246009 A AU2009246009 A AU 2009246009A AU 2009246009 A AU2009246009 A AU 2009246009A AU 2009246009 A1 AU2009246009 A1 AU 2009246009A1
Authority
AU
Australia
Prior art keywords
subject
expression
biomarker
biomarkers
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009246009A
Other languages
English (en)
Inventor
Sandy D. Der
Keyue Ding
Igor Jurisica
Lesley Seymour
Frances A. Shepherd
Dan Strumpf
Ming-Sound Tsao
Chang-qi ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of AU2009246009A1 publication Critical patent/AU2009246009A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Urology & Nephrology (AREA)
  • Evolutionary Computation (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
AU2009246009A 2008-05-14 2009-05-14 Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy Abandoned AU2009246009A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7172808P 2008-05-14 2008-05-14
US61/071,728 2008-05-14
PCT/CA2009/000650 WO2009137921A1 (en) 2008-05-14 2009-05-14 Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy

Publications (1)

Publication Number Publication Date
AU2009246009A1 true AU2009246009A1 (en) 2009-11-19

Family

ID=41318311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009246009A Abandoned AU2009246009A1 (en) 2008-05-14 2009-05-14 Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy

Country Status (6)

Country Link
US (3) US8211643B2 (https=)
EP (1) EP2288741B1 (https=)
JP (1) JP5583117B2 (https=)
AU (1) AU2009246009A1 (https=)
CA (1) CA2761571A1 (https=)
WO (1) WO2009137921A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5583117B2 (ja) 2008-05-14 2014-09-03 ユニバーシティー ヘルス ネットワーク 非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー
US20100184063A1 (en) * 2008-05-14 2010-07-22 Ming-Sound Tsao Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20110238322A1 (en) * 2008-11-03 2011-09-29 Precision Therapeutics, Inc. Methods of simulating chemotherapy for a patient
CN101705306B (zh) * 2009-12-01 2012-07-11 华中农业大学 应用as-pcr检测牛尿苷酸合酶缺乏症的方法
US9607202B2 (en) 2009-12-17 2017-03-28 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of generating trophectoderm and neurectoderm from human embryonic stem cells
WO2011160118A2 (en) * 2010-06-18 2011-12-22 Med Biogene Inc. Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US9200325B2 (en) * 2011-04-01 2015-12-01 Indiana University Research And Technology Corporation Diagnostic methods and kit for detecting cancer
RU2013157589A (ru) * 2011-05-25 2015-06-27 Новартис Аг Биомаркеры для рака легкого
CA2843887A1 (en) * 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
AU2014207429B2 (en) 2013-01-18 2018-11-01 Ellis KLINE Selective glycosidase regimen for immune programming and treatment of cancer
EP2954331B1 (en) 2013-02-11 2018-03-28 Incuron LLC Use of facilitates chromatin transcription complex (fact) in cancer
WO2014151026A1 (en) * 2013-03-15 2014-09-25 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
KR101830700B1 (ko) * 2013-11-11 2018-02-21 주식회사 파나진 클램핑 프로브 및 검출 프로브를 이용한 다중 표적핵산 검출방법
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2016003810A1 (en) 2014-07-02 2016-01-07 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
WO2016047688A1 (ja) * 2014-09-24 2016-03-31 国立研究開発法人国立がん研究センター 扁平上皮がんに対する化学放射線療法の有効性を評価するための方法
WO2016050623A1 (en) * 2014-09-29 2016-04-07 Institut Gustave Roussy Prognosis markers in lung cancer
CN106755309A (zh) * 2016-11-18 2017-05-31 北京致成生物医学科技有限公司 分子标记物在制备胰腺癌预后评估产品中的应用
JP7106810B2 (ja) * 2018-04-19 2022-07-27 学校法人 埼玉医科大学 新規肺がんマーカー
CN108949997A (zh) * 2018-08-24 2018-12-07 南京求臻基因科技有限公司 一种肺癌检测标志物及诊断试剂盒
CN109859801B (zh) * 2019-02-14 2023-09-19 辽宁省肿瘤医院 一种含有七个基因作为生物标志物预测肺鳞癌预后的模型及建立方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JP2005503145A (ja) 2001-08-16 2005-02-03 ザ ユナイテッド ステイツ オブ アメリカ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 非小細胞肺癌の分子特性
US20040241725A1 (en) 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
JP5583117B2 (ja) 2008-05-14 2014-09-03 ユニバーシティー ヘルス ネットワーク 非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー
US20100184063A1 (en) * 2008-05-14 2010-07-22 Ming-Sound Tsao Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy

Also Published As

Publication number Publication date
US20120323594A1 (en) 2012-12-20
US20160024596A1 (en) 2016-01-28
EP2288741A1 (en) 2011-03-02
EP2288741B1 (en) 2015-01-28
US20090291448A1 (en) 2009-11-26
WO2009137921A1 (en) 2009-11-19
US8211643B2 (en) 2012-07-03
EP2288741A4 (en) 2011-08-24
JP5583117B2 (ja) 2014-09-03
JP2011523549A (ja) 2011-08-18
CA2761571A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
US8211643B2 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20160032407A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
JP6824923B2 (ja) 胃腸癌での増殖の徴候及び予後
JP6404304B2 (ja) メラノーマ癌の予後予測
US20120258878A1 (en) Prognostic gene signatures for non-small cell lung cancer
EP4219765B1 (en) Prostate cancer prognosis using biomarkers
JP2020031642A (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
WO2012066451A1 (en) Prognostic and predictive gene signature for colon cancer
Linton et al. Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours
EP2304631A1 (en) Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
CA2901761A1 (en) Gene signatures for lung cancer prognosis and therapy selection
US20120077687A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
CN110291206A (zh) 用于评估前列腺癌晚期临床终点的算法和方法
JP2008529554A (ja) 固形腫瘍の予後のための薬理ゲノミクス的マーカー
Buechler et al. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor–Positive Breast Cancer
US20160281177A1 (en) Gene signatures for renal cancer prognosis
WO2010121370A1 (en) Prognostic gene expression signature for squamous cell carcinoma of the lung

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application